Company: VREOF
Filing Date: 2025-03-11
Form Type: PREM14C
Source: 0001140361-25-008065
Chunk: 165

Company: Vireo Growth Inc.
Filing Date: 2025-03-11
Form: PREM14C
Chunk 165
---
 Commission in respect of the Transaction Agreements and related transactions.

On January 23, 2025, the Company and Bill’s Nursery executed an amendment to the Bill’s Nursery MOU extending the exclusivity period to February 23, 2025.

On February 21, 2025, the Company and Bill’s Nursery executed an amendment to the Bill’s Nursery MOU, providing for a reduced payment from Bill’s Nursery of $1 million after the expiration of the exclusivity period. On February 23, 2025, the exclusivity period expired.

<div align='center'>89</div>

TABLE OF CONTENTS

Opinion of Vireo’s Financial Advisor At the meeting of the Board on December 17, 2024 to evaluate and approve the Transaction Agreements and the transactions contemplated by the Transaction Agreements, Moelis delivered an oral opinion, which was confirmed by delivery of a written opinion, dated December 17, 2024, addressed to the Board that, as of the date of the opinion and based upon and subject to the assumptions made, procedures followed, matters considered and other limitations set forth in the opinion, the consideration to be paid by Vireo to Deep Roots, Wholesome, the Proper Companies and Bill’s Nursery (the “Targets”), taken as a whole, pursuant to the Transaction Agreements (the “Consideration”), was fair, from a financial point of view, to Vireo. The Board understood that Moelis’ opinion was based upon the assumption that all of the Transactions (including the potential transaction contemplated by the Bill’s Nursery MOU) would be executed and consummated. The full text of Moelis’ written opinion dated December 17, 2024, which sets forth the assumptions made, procedures followed, matters considered and limitations on the review undertaken in connection with the opinion, is attached as Appendix A to this Information Statement and is incorporated herein by reference. Moelis’ opinion was provided solely for the use and benefit of the Board (solely in its capacity as such) in its evaluation of the Transactions. Moelis’ opinion is limited solely to the fairness to the Company, from a financial point of view, of the Consideration to be paid by Vireo to each of the Targets, and does not address Vireo’s underlying business decision to effect the Transactions or the relative merits of the Transactions as compared to any alternative business strategies or transactions that might be available to Vireo. Moelis’ opinion does not